CA2640343C - Controlled production and delivery of biologically active agents by gut bacteria - Google Patents

Controlled production and delivery of biologically active agents by gut bacteria Download PDF

Info

Publication number
CA2640343C
CA2640343C CA2640343A CA2640343A CA2640343C CA 2640343 C CA2640343 C CA 2640343C CA 2640343 A CA2640343 A CA 2640343A CA 2640343 A CA2640343 A CA 2640343A CA 2640343 C CA2640343 C CA 2640343C
Authority
CA
Canada
Prior art keywords
biologically active
ovatus
mull2
xylan
growth factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2640343A
Other languages
English (en)
French (fr)
Other versions
CA2640343A1 (en
Inventor
Simon Carding
Mark Farrar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Plant Bioscience Ltd
Original Assignee
Plant Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plant Bioscience Ltd filed Critical Plant Bioscience Ltd
Publication of CA2640343A1 publication Critical patent/CA2640343A1/en
Application granted granted Critical
Publication of CA2640343C publication Critical patent/CA2640343C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2640343A 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria Expired - Fee Related CA2640343C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0501540.9 2005-01-25
GBGB0501540.9A GB0501540D0 (en) 2005-01-25 2005-01-25 Controlled production and delivery of biologically active agents by gut bacteria
PCT/GB2006/000222 WO2006079790A2 (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Publications (2)

Publication Number Publication Date
CA2640343A1 CA2640343A1 (en) 2006-08-03
CA2640343C true CA2640343C (en) 2014-01-14

Family

ID=34259652

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2640343A Expired - Fee Related CA2640343C (en) 2005-01-25 2006-01-24 Controlled production and delivery of biologically active agents by gut bacteria

Country Status (10)

Country Link
US (1) US7988961B2 (enExample)
EP (1) EP1841875B1 (enExample)
JP (1) JP4989490B2 (enExample)
KR (1) KR101291960B1 (enExample)
AT (1) ATE483811T1 (enExample)
CA (1) CA2640343C (enExample)
DE (1) DE602006017331D1 (enExample)
ES (1) ES2353721T3 (enExample)
GB (1) GB0501540D0 (enExample)
WO (1) WO2006079790A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008317000B2 (en) * 2007-10-26 2014-10-23 Brenda E. Moore Probiotic compositions and methods for inducing and supporting weight loss
EP2258844A1 (en) 2009-05-28 2010-12-08 Helmholtz Zentrum Für Infektionsforschung Tumour-specific bacterial promoter elements
CN102462837B (zh) * 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
US10047405B2 (en) 2013-12-20 2018-08-14 President And Fellows Of Harvard College Engineered genetic enteric sensor bacteria and uses thereof
US9688967B2 (en) 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2016106343A1 (en) * 2014-12-22 2016-06-30 Massachusetts Institute Of Technology Probiotic organisms for diagnosis, monitoring, and treatment of inflammatory bowel disease
US20160206666A1 (en) 2014-12-22 2016-07-21 Synlogic, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
JP7095993B2 (ja) * 2015-03-02 2022-07-05 シンロジック オペレーティング カンパニー インコーポレイテッド 消化管炎症低下および／または消化管粘膜バリア強化の利益を享受する疾患処置のために操作された細菌
EP3294760B1 (en) 2015-05-13 2021-03-24 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11685925B2 (en) 2015-10-30 2023-06-27 Synlogic Operating Company, Inc. Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
AU2016356684C1 (en) 2015-11-16 2022-11-10 Synlogic Operating Company, Inc. Bacteria engineered to reduce hyperphenylalaninemia
US11766461B2 (en) 2016-04-20 2023-09-26 The Board of Trustees of the Stanford Junior Compositions and methods for nucleic acid expression and protein secretion in Bacteroides
EP3554518A4 (en) 2016-12-15 2020-07-29 The Board of Trustees of the Leland Stanford Junior University COMPOSITIONS AND METHODS FOR MODULATING THE GROWTH OF A GENETICALLY MODIFIED INTESTINAL BACTERIAL CELL
WO2018152133A1 (en) * 2017-02-14 2018-08-23 California Institute Of Technology Modulation of microbial synthesis of 4-etylphenol and 4-ethylphenol sulfate in behavior and disease
WO2018152306A1 (en) * 2017-02-15 2018-08-23 President And Fellows Of Harvard College Modulation of host immune cell populations using gut microbiota
WO2018183685A1 (en) * 2017-03-29 2018-10-04 President And Fellows Of Harvard College Methods of regulating gene expression in a cell
BR112021011221A2 (pt) 2018-12-10 2021-08-31 Novome Biotechnologies, Inc. Métodos e composições para tratar hiperoxalúria
JP2023518184A (ja) 2020-03-20 2023-04-28 シンロジック オペレーティング カンパニー インコーポレイテッド 高フェニルアラニン血症を軽減するように遺伝子改変された微生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0569604A1 (en) * 1992-04-07 1993-11-18 Societe Des Produits Nestle S.A. Integrative gene-expression in Streptococcus salivarius ssp.thermophilus
ATE356217T1 (de) * 1999-09-10 2007-03-15 Secr Defence Rekombinante mikroorganismen
JP2001275680A (ja) * 2000-03-31 2001-10-09 Yakult Honsha Co Ltd β−１，３−キシラナーゼ遺伝子、該遺伝子を導入した微生物、及びβ−１，３−キシラナーゼの製造法
JP2003144200A (ja) * 2001-11-07 2003-05-20 Yakult Honsha Co Ltd バクテロイデスグループ細菌用プローブおよびこれを用いた検出方法

Also Published As

Publication number Publication date
ES2353721T3 (es) 2011-03-04
GB0501540D0 (en) 2005-03-02
JP4989490B2 (ja) 2012-08-01
JP2008527988A (ja) 2008-07-31
ATE483811T1 (de) 2010-10-15
WO2006079790A2 (en) 2006-08-03
CA2640343A1 (en) 2006-08-03
DE602006017331D1 (de) 2010-11-18
EP1841875B1 (en) 2010-10-06
EP1841875A2 (en) 2007-10-10
WO2006079790A3 (en) 2006-12-21
KR101291960B1 (ko) 2013-08-09
US20080131402A1 (en) 2008-06-05
KR20070108882A (ko) 2007-11-13
US7988961B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
CA2640343C (en) Controlled production and delivery of biologically active agents by gut bacteria
AU2017202497B2 (en) Bacterium for use as a probiotic for nutritional and medical applications
Waidmann et al. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice
KR102377396B1 (ko) Th17 세포의 유도를 위한 조성물 및 방법
CA2738781C (en) Reduced colonization of microbes at the mucosa
CN103221420A (zh) 用于递送治疗性肽的组合物和方法
US20120144509A1 (en) Novel strains of helicobacter pylori and uses thereof
Farrar et al. Engineering of the gut commensal bacterium Bacteroides ovatus to produce and secrete biologically active murine interleukin‐2 in response to xylan
CN102281895A (zh) 用于肠产毒性大肠杆菌导致的猪断奶后腹泻的疫苗
JP2009506079A (ja) 生理活性ポリペプチドの細菌性送達
EP3506932A1 (en) Genetically modified bacteria stably expressing il-10 and insulin
WO2014037505A1 (en) Probiotic bacteria as carrier for a helminth-derived immunomodulator for the treatment of inflammatory disorders
EP3237602B1 (en) Method of culturing segmented filamentous bacteria in vitro
Kajikawa et al. Adjuvant effects for oral immunization provided by recombinant Lactobacillus casei secreting biologically active murine interleukin-1β
EP2597151A2 (en) Recombinant microorganisms, methods for preparing vaccine strains, antigens, and vector vaccine compositions of same, uses thereof, and related antibodies, diagnostic kit, and treatment and/or prophylactic methods
Rottiers et al. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis
CN101052705A (zh) 自身遏制性乳杆菌菌株
Ogita et al. Suppression of Th17 response by Streptococcus thermophilus ST28 through induction of IFN-γ
Li et al. Yeast surface display of Escherichia coli enterotoxin and its effects of intestinal microflora and mucosal immunity
Bienenstock et al. Probiotic therapies
Steidler et al. Genetically modified Lactococcus lactis: novel tools for drug delivery
CN105770868A (zh) 重组乳酸菌及SNase在制备预防或治疗1型糖尿病药物中的应用
CN107073106A (zh) 用于治疗泌尿生殖系统癌症的减毒或失活病原性大肠杆菌
Steidler et al. In situ delivery of therapeutic proteins by recombinant Lactococcus lactis
Remaut et al. Clinical potential of Lactococcus lactis mediated delivery of human interleukin-10 and trefoil factors

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170124